J4D.F Kenvue Inc.
- Market cap
- EUR 33.4B
- P/E
- 22.9x
- P/B
- 3.67x
- ROE
- 17.8%
- Dividend yield
- 4.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is J4D.F undervalued?
Graham numberJ4D.F trades 93.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kenvue Inc. fundamental analysis
No fundamental analysis for Kenvue Inc. yet.
Kenvue Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telem…
Full company profileKenvue Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kenvue Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 15.1B | 15.0B | 15.4B | 15.5B | 15.1B | 15.7B |
| Gross Profit | 8.42B | 8.29B | 8.64B | 8.96B | 8.79B | 9.22B |
| Operating Income | 3.03B | 2.69B | 2.49B | 2.63B | 2.72B | 3.11B |
| EBITDA | - | 3.28B | 3.18B | 2.47B | 2.99B | 3.50B |
| Net Income | 2.08B | 2.06B | 1.66B | 1.03B | 1.47B | 1.81B |
| EPS | 1.10 | 1.09 | 0.87 | 0.54 | 0.77 | 0.94 |
| Balance Sheet | ||||||
| Total Assets | 27.9B | 27.3B | 27.9B | 25.6B | 27.1B | 26.7B |
| Total Liabilities | 7.53B | 7.35B | 16.6B | 15.9B | 16.3B | 16.5B |
| Shareholders' Equity | 20.4B | 20.0B | 11.2B | 9.67B | 10.8B | 10.2B |
| Cash & Short-term Investments | 740M | 1.23B | 1.38B | 1.07B | 1.06B | 1.04B |
| Cash Flow | ||||||
| Operating Cash Flow | 334M | 2.53B | 3.17B | 1.77B | 2.20B | 2.50B |
| Capital Expenditure | 295M | 375M | 469M | 434M | 475M | 377M |
| Free Cash Flow | 39.0M | 2.15B | 2.70B | 1.34B | 1.72B | 2.13B |
| Ratios | ||||||
| ROE | 10.2% | 10.3% | 14.8% | 10.7% | 13.7% | 17.8% |
| ROA | 7.4% | 7.6% | 6.0% | 4.0% | 5.4% | 6.8% |
| Net Profit Margin | 13.8% | 13.8% | 10.8% | 6.7% | 9.7% | 11.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Kenvue Inc. dividends
- Dividend yield
- 4.30%
- Forward dividend
- 0.75 EUR
- Payout ratio
- 107.6%
- Ex-dividend date
- Sep 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.58B | 0.83 | 107.6% |
| 2024 | USD 1.55B | 0.81 | 150.7% |
| 2023 | USD 14.6B | 7.60 | 874.6% |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Kenvue Inc.
- Insiders 0.08%
- Institutions 95.53%
- Public & others 4.40%
- Shares outstanding 1.92B
- Free float 1.92B
Kenvue Inc. company profile
- Company name
- Kenvue Inc.
- Ticker
- J4D.F
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Employees
- 21,780
- Fiscal year end
- December
- Address
- 1 Kenvue Way, Summit, NJ, United States, 07901
- Phone
- 908 874 1200
- Website
- kenvue.com
About Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Kenvue Inc. management
10- Mr. Kirk L. PerryCEO & Director · born 1967
- Mr. Michael P. WondraschChief Technology & Data Officer · born 1969
- Mr. Matthew OrlandoGeneral Counsel · born 1977
- Mr. Carlton LawsonGroup President of Europe, Middle East & Africa · born 1969
- Ms. Heather R. HowlettInterim CFO & Chief Accounting Officer · born 1978
- Ms. Meredith StevensChief Operations Officer · born 1963
- Dr. Caroline Tillett Ph.D.Chief Scientific Officer · born 1972
- Mr. Jonathan HalvorsonChief Digital & Marketing Officer · born 1983
- Mr. Anil AgarwalHead of Total Rewards
- Mr. Russell DyerChief Corporate Affairs Officer · born 1981